[1] |
孙玉环,车宗刚,郑家伟. ISSVA 2018脉管异常新分类[J]. 中国口腔颌面外科杂志, 2019, 17(1): 13-19.
|
[2] |
Zukerberg LR, Nickoloff BJ, Weiss SW. Kaposiform hemangioendothelioma of infancy and childhood. An aggressive neoplasm associated with Kasabach-Merritt syndrome and lymphangiomatosis[J]. Am J Surg Pathol, 1993, 17(4): 321-328.
|
[3] |
Croteau SE, Liang MG, Kozakewich HP, et al. Kaposiform hemangioendothelioma: atypical features and risks of Kasabach-Merritt phenomenon in 107 referrals[J]. J Pediatr, 2013, 162(1): 142-147.
|
[4] |
Sarkar M, Mulliken JB, Kozakewich HP, et al. Thrombocytopenic coagulopathy (Kasabach-Merritt phenomenon) is associated with Kaposiform hemangioendothelioma and not with common infantile hemangioma[J]. Plast Reconstr Surg, 1997, 100(6): 1377-1386.
|
[5] |
Ji Y, Yang K, Peng S, et al. Kaposiform haemangioendothelioma: clinical features, complications and risk factors for Kasabach-Merritt phenomenon[J]. Br J Dermatol, 2018, 179(2): 457-463.
|
[6] |
Dasgupta R, Fishman SJ. ISSVA classification[J]. Semin Pediatr Surg, 2014, 23(4): 158-161.
|
[7] |
Nakaya T, Morita K, Kurata A, et al. Multifocal Kaposiform hemangioendothelioma in multiple visceral organs: An autopsy of 9-day-old female baby[J]. Hum Pathol, 2014, 45(8): 1773-1777.
|
[8] |
Ryu YJ, Choi YH, Cheon JE, et al. Imaging findings of Kaposiform hemangioendothelioma in children[J]. Eur J Radiol, 2017, 86: 198-205.
|
[9] |
Drolet BA, Trenor CC, 3rd, Brandão LR, et al. Consensus-derived practice standards plan for complicated Kaposiform hemangioendothelioma[J]. J Pediatr, 2013, 163(1): 285-291.
|
[10] |
El-Sayed M, Ramadan M. Immunohistochemical study of some rare vascular tumors[J]. J Egypt Natl Canc Inst, 2004, 16(2): 123-129.
|
[11] |
Gruman A, Liang MG, Mulliken, JB, et al. Kaposiform hemangioendothelioma without Kasabach-Merritt phenomenon[J]. J Am Acad Dermatol, 2005, 52(4): 616-622.
|
[12] |
Duan L, Renzi S, Weidman D, et al. Sirolimus treatment of an infant with intrathoracic Kaposiform hemangioendothelioma complicated by life-threatening pleural and pericardial effusions[J]. J Pediatr Hematol Oncol, 2020, 42(1): 74-78.
|
[13] |
Tlougan BE, Lee MT, Drolet BA, et al. Medical management of tumors associated with Kasabach-Merritt phenomenon: An expert survey[J]. J Pediatr Hematol Oncol, 2013, 35(8): 618-622.
|
[14] |
Jiang RS, Hu R. Successful treatment of Kasabach-Merritt syndrome arising from Kaposiform hemangioendothelioma by systemic corticosteroid therapy and surgery[J]. Int J Clin Oncol, 2012, 17(5): 512-516.
|
[15] |
Liu X, Li J, Qu X, et al. Clinical outcomes for systemic corticosteroids versus vincristine in treating Kaposiform hemangioendothelioma and tufted angioma[J]. Medicine (Baltimore), 2016, 95(20): e3431.
|
[16] |
Ji Y, Chen S, Xiang B, et al. Sirolimus for the treatment of progressive Kaposiform hemangioendothelioma: A multicenter retrospective study[J]. Int J Cancer, 2017, 141(4): 848-855.
|
[17] |
George ME, Sharma V, Jacobson J, et al. Adverse effects of systemic glucocorticosteroid therapy in infants with hemangiomas[J]. Arch Dermatol, 2004, 140(8): 963-969.
|
[18] |
Fahrtash F, McCahon E, Arbuckle S. Successful treatment of Kaposiform hemangioendothelioma and tufted angioma with vincristine[J]. J Pediatr Hematol Oncol, 2010, 32(6): 506-510.
|
[19] |
Peng S, Yang K, Xu Z, et al. Vincristine and sirolimus in the treatment of Kaposiform haemangioendothelioma[J]. J Paediatr Child Health, 2019, 55(9): 1119-1124.
|
[20] |
Hartman KR, Moncur JT, Minniti CP, et al. Mediastinal Kaposiform hemangioendothelioma and Kasabach-Merritt phenomenon in an infant: treatment with interferon[J]. J Pediatr Hematol Oncol, 2009, 31(9): 690-692.
|
[21] |
Wang Z, Yao W, Sun H, et al. Sirolimus therapy for Kaposiform hemangioendothelioma with long-term follow-up[J]. J Dermatol, 2019, 46(11): 956-961.
|
[22] |
Wang P, Zhou W, Tao L, et al. Clinical analysis of Kasabach-Merritt syndrome in 17 neonates[J]. BMC Pediatr, 2014, 14: 146.
|
[23] |
Traivaree C, Lumkul R, Torcharus K, et al. Outcome of Kasabach-Merritt phenomenon: the role of vincristine as monotherapy: report of a case[J]. J Med Assoc Thai, 2012, 95(Suppl 5): S181-S185.
|
[24] |
Acharya S, Pillai K, Francis A, et al. Kasabach-Merritt syndrome: management with interferon[J]. Indian J Dermatol, 2010, 55(3): 281-283.
|
[25] |
Dubois J, Hershon L, Carmant L, et al. Toxicity profile of interferon alfa-2b in children: A prospective evaluation[J]. J Pediatr, 1999, 135(6): 782-785.
|
[26] |
Garcia-Monaco R, Giachetti A, Peralta O, et al. Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon: successful treatment with embolization and vincristine in two newborns[J]. J Vasc Interv Radiol, 2012, 23(3): 417-422.
|
[27] |
Blatt J, Stavas J, Moats-Staats B, et al. Treatment of childhood Kaposiform hemangioendothelioma with sirolimus[J]. Pediatr Blood Cancer, 2010, 55(7): 1396-1398.
|
[28] |
Hammill AM, Wentzel M, Gupta A, et al. Sirolimus for the treatment of complicated vascular anomalies in children[J]. Pediatr Blood Cancer, 2011, 57(6): 1018-1024.
|
[29] |
Li K, Tai M, Qin Z, et al. Clinical observations in mesh suture treatment for infants of Kasabach-Merritt phenomenon[J]. J Paediatr Child Health, 2015, 51(5): 529-533.
|